Online first
Research Letter
Published online: 2025-03-10
The role of endomyocardial biopsy for surveillance of cardiac allograft rejection: time to move on?
1
, 1, 1, 1, 1, 1, 1, 1, 1
, 1, 1, 1, 1, 1, 1, 1, 1
DOI: 10.5603/cj.99019
Pubmed: 40062925
Abstract
Not available
Keywords: Endomyocardial biopsycellular rejectionhumoral rejectioninmmunosupresionnon-invasive diagnosis
References
- Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023; 42(5): e1–e141.
- Holzhauser L, DeFilippis EM, Nikolova A, et al. The End of Endomyocardial Biopsy?: A Practical Guide for Noninvasive Heart Transplant Rejection Surveillance. JACC Heart Fail. 2023; 11(3): 263–276.
- Strecker TRJ, Weyand M, Agaimy A, et al. Endomyocardial biopsy for monitoring heart transplant patients: 11-years-experience at a german heart center. Int J Clin Exp Pathol. 2013; 6(1): 55–65.
- Cusi V, Vaida F, Wettersten N, et al. Benefit versus Risk of Endomyocardial Biopsy for Heart Transplant Patients in the Contemporary Era. medRxiv. 2023.
- Ortiz-Bautista C, Fernández-Avilés F, Delgado Jiménez JF. Serum biomarkers of acute rejection: Towards precision medicine in heart transplant. J Heart Lung Transplant. 2021; 40(10): 1090–1097.
- Henricksen EJ, Moayedi Y, Purewal S, et al. Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation. Clin Transplant. 2023; 37(3): e14699.
